Work

926 Degradable cyclic amino alcohol lipids enable lymphoid delivery for potent influenza and cancer mRNA vaccines

Year: 2026
Type: conference-abstract
Abstract: Background The success of COVID-19 mRNA vaccines, now safely administered to billions of people, highlights the broad clinical potential of mRNA vaccine platforms. Further improving vaccine potency could promote robust immunity at lower doses while reducing manufacturing demands and minimizing side effects. Ionizable lipids are central to this goal by promoting endosomal escape, enhancing protein expression, enabling tissue-selective delivery, and supporting tolerability. Although clinically used lipids such as SM-102 have established important benchmarks, advances beyond current formulations remain limited. To address this gap, we developed next-generation ionizable lipids designed to enhance mRNA delivery to antigen-presenting cells (APCs) and lymphoid organs, including lymph nodes and spleen, where adaptive immune responses are initiated.Methods We employed a hybrid rational-design and combinatorial strategy to generate structurally unique ionizable lipids for mRNA vaccination. Biodegradable lipid libraries were synthesized using glycidyl ester-functionalized hydrocarbon tails and constrained cyclic secondary amines. Lead candidates were subsequently optimized through medicinal chemistry-guided structure–activity studies to identify formulations with improved delivery and immunogenicity.Results Systematic optimization identified AMG1541, a next-generation ionizable lipid that achieved 4.5-fold higher mRNA expression than AMG104 and significantly outperformed benchmark lipids SM-102 and cKK-E12. AMG1541 combines superior potency with favorable pharmacokinetics through biodegradable ester tails that promote rapid clearance and reduced liver accumulation. Compared with SM-102, AMG1541 generated 3.5-fold higher expression at the injection site and 8.3-fold lower expression in the liver. In mice, AMG1541 elicited comparable neutralizing immune responses at 100-fold lower doses than SM-102, potentially reducing both manufacturing costs and dose-related toxicities. Enhanced lymph node drainage and improved APC transfection amplified germinal center responses and antibody production, highlighting the importance of lymphoid delivery for vaccine efficacy ( figure 1).To further improve systemic cancer vaccination, we developed AMG514, a spleen-targeting spirocyclic amine lipid. AMG514 achieved approximately fourfold higher splenic delivery and enhanced APC transfection compared with cKK-E12. Vaccination with AMG514-formulated OVA mRNA generated approximately 2.5-fold stronger antigen-specific CD8+ T-cell responses and resulted in complete protection against B16-OVA tumor challenge.Conclusions These degradable ionizable lipids substantially enhance mRNA vaccine potency and provide valuable design principles for next-generation delivery systems. By improving lymphoid tissue targeting, APC transfection, and immune activation, these formulations have broad potential for both infectious disease vaccines and cancer immunotherapy.Abstract 926 Figure 1Combinatorial lipid library for developing potent mRNA vaccines
Language: English
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W7225189824
Cites:
Cited by:
Related to: 10